HESI TECHNICAL COMMITTEE ON IMAGING FOR TRANSLATIONAL SAFETY ASSESSMENT
The mission of the HESI Technical Committee on Translational Imaging in Safety Assessment is to build a multi-sector and multi-specialty team of scientists to identify and pursue opportunities to impactfully integrate imaging approaches into current safety assessment paradigms for drugs and/or hazard assessment approaches for chemicals.
| Committee Factsheet
Committee Presentations and Data Resources
2014-2015 Participating Organizations
Astellas Pharma Inc.
AstraZeneca Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Duke University Center for In Vivo Microscopy
Hoffman-La Roche Inc.
National Institutes of Health (US)
Seoul National University
Takeda Pharmaceutical Company Limited
University of North Carolina - Chapel Hill
US Environmental Protection Agency
US Food and Drug Administration
Recent Committee Publications
Drug-induced liver injury (DILI) is a leading cause of acute liver failure and transplantation. DILI can be the result of impaired hepatobiliary transporters, with altered bile formation, flow, and subsequent cholestasis.
Johnson GA, Calabrese E, Little PB, Hedlund L, Qi Y, Badea A: Quantitative mapping of trimethyltin injury in the rat brain using magnetic resonance histology. Neurotoxicology 2014, 42C:12-23. More details
G. Allan Johnson, PhD
Teyent Getaneh, email@example.com